Do you want to read an article? Please log in or register.
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
Lung, Respiratory and Thoracic Cancer
Related content
Lung, Respiratory and Thoracic Cancer
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
J Clin Oncol
Awad MM, Forde PM, Girard N, Spicer J, Wang C, Lu S, Mitsudomi T, Felip E, Broderick SR, Swanson SJ, Brahmer J, Kerr K, Saylors GB, Chen KN, Gharpure V, Neely J, Balli D, Hu N, Provencio Pulla M
doi: 10.1200/JCO-24-02239
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
★ 2
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lancet
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S, KEYNOTE-671 Investigators
doi: 10.1016/S0140-6736(24)01756-2
Lung, Respiratory and Thoracic Cancer
Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis
Cancers (Basel)
Girard N, Besada M, Rogula B, Lucherini S, Vo L, Chaudhary MA, Goring S, Lozano-Ortega G, Tran M, Varol N, Waser N, Lee JM, Spicer J
doi: 10.3390/cancers16132492
Lung, Respiratory and Thoracic Cancer
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1
J Thorac Oncol
Peters S, Regan MM, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Brahmer JR, Penrod JR, Li J, Tracy L, Yuan Y, Bushong J, Lee A, Eccles LJ, Ray S, Ramalingam SS
doi: 10.1016/j.jtho.2025.05.019
SPECIAL REPORT
Lung, Respiratory and Thoracic Cancer
Neoadjuvant Nivolumab plus chemotherapy in resectable NSCLC
Lung, Respiratory and Thoracic Cancer
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial
Lung Cancer
Lee KH, Lee JS, Sugawara S, Kang JH, Kim HR, Inui N, Hida T, Yoshida T, Tanaka H, Yang CT, Inoue T, Nishio M, Ohe Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Takahashi S, Nakagawa K
doi: 10.1016/j.lungcan.2025.108109
Gastrointestinal Cancer
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY
J Clin Oncol
Kang YK, Kim HD, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Cheong JH, Jeong O, Heo MH, Kim HK, Park C, Yoo CH, Kang SY, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Hwang JE, Ryu SW, Kook MC, Ryoo BY, Kim H, Yoo MW, Lee NS, Lee SH, Noh SH
doi: 10.1200/JCO.23.02167
Lung, Respiratory and Thoracic Cancer
Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study
Clin Cancer Res
Mack PC, Redman MW, Tukachinsky H, Kozono DE, Minichiello K, Dragnev KH, Tolba KA, Neal JW, Madison RW, Waqar SN, Aggarwal C, Hirsch FR, Patel JD, Herbst RS, Chiang AC, Reckamp KL, Kelly K, Borghaei H, Gray JE, Gandara DR
doi: 10.1158/1078-0432.CCR-24-3658
Lung, Respiratory and Thoracic Cancer
Delayed central nervous system progression with atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer (LU23-15)
Lung Cancer
Lee K, Kim TH, Yong Lee S, Lee YG, Choi J, Choi JH, Yoon Choi J, Lim AR, Sun Kim J, Won Lee J, Ji Choi Y, Hyun Park J, Namgung Y, Kyung Ahn H, Joo Kang E
doi: 10.1016/j.lungcan.2025.108455